NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult population with relapsed or refractory multiple ...

Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its secondary ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

The FDA accepted a BLA for Blenrep combinations for multiple myeloma treatment after prior therapy. DREAMM-7 and DREAMM-8 trials showed significant improvements in progression-free survival and ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...